SLXN (Silexion Therapeutics) Other Income (Expense) : $0.90 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics Other Income (Expense)?

Silexion Therapeutics's other income expense for the Silexion Therapeutics's pretax income for the three months ended in Dec. 2024 was $0.18 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.90 Mil.

Silexion Therapeutics Other Income (Expense) Historical Data

The historical data trend for Silexion Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics Other Income (Expense) Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Other Income (Expense)

0.37

-0.54

0.90

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Income (Expense)	Get a 7-Day Free Trial				-0.02	-0.19	-0.11	1.02	0.18

Silexion Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.90 Mil.

Silexion Therapeutics (NAS:SLXN) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Abba Hillel Road, Ramat-Gan, ISR, 5250606

Website

https://silexion.com

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.